A Link Between Air Pollution and Dementia Risk Is Supplied by New Data.

Published Date: 23 Apr 2023

According to the study, prolonged exposure to nitrogen dioxide, particulate matter PM2.5, and nitrogen oxide may raise the risk of dementia.

Read Full News

Latest News

Advancing NP and PA Involvement in Pulmonary Care, CHEST Learning Susan Corbridge, PhD, Alanna Kavanugh, MSN, CCRN

Susan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.

Thunderstorms Linked to Surge in Asthma ER Visits

Thunderstorms Linked to Surge in Asthma ER Visits

House Dust Mite SLIT Tablet Well Tolerated in Children With Allergic Asthma

House Dust Mite SLIT Tablet Well Tolerated in Children With Allergic Asthma

5 Pulmonology Headlines You Missed in November 2025

5 Pulmonology Headlines You Missed in November 2025

Nalbuphine Extended-Release Reduces Chronic Cough in IPF, with Philip Molyneaux, MBBS Philip Molyneaux, MBBS

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Todays Updates

Episode 156: Building Better Mood and Behavior Care for Parkinson Disease Marco Meglio, Sneha Mantri, MD, MS

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis Isabella Ciccone, MPH

Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.

Weight-Adjusted Waist Index Can Predict CVD Risk in Cardiovascular Kidney Metabolic Syndrome

Weight-Adjusted Waist Index Can Predict CVD Risk in Cardiovascular Kidney Metabolic Syndrome

Todays Updates

Episode 156: Building Better Mood and Behavior Care for Parkinson Disease Marco Meglio, Sneha Mantri, MD, MS

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis Isabella Ciccone, MPH

Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.

Weight-Adjusted Waist Index Can Predict CVD Risk in Cardiovascular Kidney Metabolic Syndrome

Weight-Adjusted Waist Index Can Predict CVD Risk in Cardiovascular Kidney Metabolic Syndrome

Latest News

Susan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.

Thunderstorms Linked to Surge in Asthma ER Visits

House Dust Mite SLIT Tablet Well Tolerated in Children With Allergic Asthma

5 Pulmonology Headlines You Missed in November 2025

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

News All Time

Redefining Severe Airway Disease Care: Clinicians Weigh In on Biologics and Barriers Victoria Johnson

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

FDA Approval Adds Tezepelumab to CRSwNP Treatment Landscape Victoria Johnson

Tezepelumab is the first TSLP-targeting biologic to be approved for chronic rhinosinusitis with nasal poylps.

Sleep Apnea Significantly Impacts Mortality Benefit of GLP-1s Kevin Kunzmann

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

4 Trials That May Change Pulmonary Embolism, with Parth Rali, MD Parth Rali, MD

Rali highlights a series of randomized, controlled trials that could reinvigorate the recently stagnant field of PE treatment development.

The Case for More Spirometry, Pulmonary Function Testing, with Meredith McCormack, MD Kevin Kunzmann

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

Dupilumab, Tezepelumab Provide Consistent Real-World Severe Asthma Outcomes Kevin Kunzmann

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.

Opportunities to Define and Treat Indoor Air Quality, with Sarath Raju, MD, MPH Sarath Raju, MD, MPH

Most clinicians are not considering poor home air exposure when treating persistent asthma or airway disease, Raju explains. That may be making a difference in outcomes.

Clinical and Patient Definitions of Acute COPD Exacerbation Recovery Differ Greatly Kevin Kunzmann

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

Guidelines in Review: CHEST Advises Against Routine Blood Transfusions for Critically Ill Patients During Procedures Kevin Kunzmann

Evidence-based guidelines from emphasize personalized transfusion strategies for critically ill patients, urging clinicians to avoid routine platelet and fresh frozen plasma transfusions during common procedures.

What Ails Lung Cancer Screening, with Douglas Wood, MD Douglas Wood, MD

Wood shares 3 factors that influencing our nationally poor rates of high-risk lung cancer screening.

Dry Powder Treprostinil Tolerated Among Patients with PH-ILD, with Nicholas Kolaitis, MD Kevin Kunzmann

Kolaitis discussed interim findings from the ASCENT trial, which showed ability to increase treprostinil dosing while maintaining a safe and efficacious profile.

Baseline Type 2 Biomarkers Can Predict Asthma Remission with Dupilumab, with Mario Castro, MD, MPH Kevin Kunzmann

Castro discusses new data from CHEST 2025 showing the value of baseline blood eosinophils and FeNO in understanding potential dupilumab outcomes.

Extended-Release Nalbuphine Improves Patient-Reported Refractory Chronic Cough Within 1 Week Imran Satia, MD, PhD

Imran Satia, MD, PhD, discusses promising phase 2A trial data showing quick and significant improvements in patients' perception of cough frequency and severity.

Dupilumab Lessens COPD Exacerbation Impact, with Nicola Hanania, MD, MS Nicola Hanania, MD, MS

Hanania discusses the pooled BOREAS and NOTUS post hoc data showing dupilumab protects lung function before and after COPD exacerbations.

Dupilumab Reduces Mucus Burden in Uncontrolled Asthma, with Njira Lugogo, MD Njira Lugogo, MD

Mucus plugs are an increasingly present issue in uncontrolled asthma. Lugogo discusses promising findings from VESTIGE that addresses them.

Aroxybutynin and Atomoxetine (AD109) Reduces Obstructive Sleep Apnea Burden in Phase 3 SynAIRgy Kevin Kunzmann

Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.

Recommended News For You

For the treatment of vestibular schwannomas in neurofibromatosis type 2, stereotactic radiosurgery has been found to be effective.

Clinical trial is testing whether heavy lifting could combat cancer side effects

Efanesoctocog Alfa Prevented Bleeding in Kids With Severe Hemophilia A

Olaparib-Abiraterone in mCRPCs Selected by Biomarkers Outperforms Each Agent by Itself.

"Unusual" Cancers Following Pandemic; Triumph in TNBC; Clinical Trial Interrupted by Shortage.

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination

Recommended Articles For You

Immunotherapy Breakthroughs: Transforming Cancer Care Across All Oncology Fields 

Liquid Biopsy in Oncology: Innovations in Cancer Detection, Monitoring, and Clinical Use 

The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder  

Myeloproliferative Disorders: Causes, Symptoms and Treatment Options  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study finds that AI is better at forecasting the risk of developing cancer.

2.

Pickleball program boosts health and wellness for cancer survivors, study finds

3.

In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.

4.

Durvalumab Wins FDA Approval in Limited-Stage SCLC

5.

Childhood cancer survivors face new health problems later in life, study shows

1.

Oncology Trials Roadmap: From Drug Discovery to Delivery and Patient Access

2.

Understanding Mean Corpuscular Volume: A Comprehensive Guide 

3.

The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective

4.

Exosomes in Cancer: A Novel Frontier for Therapy and Biomarker Discovery

5.

Unlocking the Mystery of Ovarian Cancer Staging

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII

2.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

3.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

5.

Role of Nimotuzumab in Management of Nasopharyngeal Cancer


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot